Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial.
Gao HF, Wu Z, Lin Y, Song XY, Cao Y, Chen QJ, Zhang G, Fu P, Liu Z, Zhang LL, Yang CQ, Yang M, Zhu T, Ji F, Li JQ, Cheng MY, Wang K. Gao HF, et al. Among authors: li jq. Ther Adv Med Oncol. 2021 Apr 20;13:17588359211009003. doi: 10.1177/17588359211009003. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33959195 Free PMC article.
Risk of breast cancer-related death in women with a prior cancer.
Ji F, Yang CQ, Li XL, Zhang LL, Yang M, Li JQ, Gao HF, Zhu T, Cheng MY, Li WP, Wu SY, Zhong AL, Wang K. Ji F, et al. Among authors: li xl, li jq, li wp. Aging (Albany NY). 2020 Apr 6;12(7):5894-5906. doi: 10.18632/aging.102984. Epub 2020 Apr 6. Aging (Albany NY). 2020. PMID: 32250967 Free PMC article.
DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations.
Yang M, Fan Y, Wu ZY, Gu J, Feng Z, Zhang Q, Han S, Zhang Z, Li X, Hsueh YC, Ni Y, Li X, Li J, Hu M, Li W, Gao H, Yang C, Zhang C, Zhang L, Zhu T, Cheng M, Ji F, Xu J, Cui H, Tan G, Zhang MQ, Liang C, Liu Z, Song YQ, Niu G, Wang K. Yang M, et al. EBioMedicine. 2021 Jul;69:103446. doi: 10.1016/j.ebiom.2021.103446. Epub 2021 Jun 19. EBioMedicine. 2021. PMID: 34157485 Free PMC article.
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K. Zhang L, et al. Int J Cancer. 2022 Feb 15;150(4):654-662. doi: 10.1002/ijc.33830. Epub 2021 Oct 7. Int J Cancer. 2022. PMID: 34591977 Clinical Trial.
1,358 results